# BCL2L12

## Overview
BCL2L12 is a gene that encodes the BCL2-like 12 protein, a member of the BCL-2 family known for its involvement in the regulation of apoptosis, a critical process for maintaining cellular homeostasis. The BCL2-like 12 protein is characterized by its proline-rich regions and a BH2 domain, distinguishing it from other BCL-2 family members that typically contain multiple BCL-2 homology domains. This protein plays a significant role in modulating apoptotic pathways, particularly through its interactions with key regulatory proteins such as p53 and effector caspases, thereby influencing cell survival and death mechanisms. BCL2L12 is expressed in various human tissues and has been implicated in several cancers, including glioblastoma multiforme, chronic lymphocytic leukemia, and breast cancer, where it serves as a potential prognostic marker due to its impact on apoptosis and tumor progression (Talieri2003Expression; Scorilas2001Molecular; Stegh2010Glioma).

## Structure
The BCL2L12 protein is a member of the BCL-2 family, characterized by its proline-rich regions and a highly conserved BH2 domain. It is composed of 334 amino acids, with a molecular mass of 36.8 kDa and an isoelectric point of 9.45 (Chou2012GSK3β; Scorilas2001Molecular). The protein contains a BH2 homology domain but lacks the BH1, BH3, and BH4 domains, which are common in other BCL-2 family members (Stegh2011Beyond; Scorilas2001Molecular). BCL2L12 also features five PXXP tetrapeptide sequences, which are proline-rich motifs (Scorilas2001Molecular).

Post-translational modifications of BCL2L12 include phosphorylation by GSK3β at Ser156, which is crucial for its anti-apoptotic function (Chou2012GSK3β). The protein is also subject to potential O-glycosylation and N-myristoylation (Scorilas2001Molecular). BCL2L12 has two splice variants: the full-length BCL2L12 and BCL2L12A, which lacks exon 3 and encodes a truncated isoform of 176 amino acids (Chou2012GSK3β; Papageorgiou2011The). The BCL2L12A variant does not contain the BH2 domain and does not interact with GSK3β (Chou2012GSK3β). The protein's nuclear localization and interaction with p53 suggest additional molecular functions beyond caspase inhibition (Stegh2011Beyond).

## Function
The BCL2L12 gene encodes a protein that is a member of the BCL-2 family, which is involved in the regulation of apoptosis, a process of programmed cell death crucial for maintaining cellular homeostasis and development. BCL2L12 contains a proline-rich region and a BH2 domain, which are characteristic of the BCL-2 family proteins. These structural features suggest that BCL2L12 may interact with other proteins to regulate apoptotic pathways, although its exact role in apoptosis is not fully understood (Talieri2003Expression; Scorilas2001Molecular).

In healthy human cells, BCL2L12 is expressed in various tissues, including the breast, thymus, prostate, and bone marrow, indicating its widespread role in cellular processes (Scorilas2001Molecular; Korbakis2012Quantitative). The protein is primarily active in the cytoplasm and nucleus, where it influences processes such as cell cycle regulation and DNA repair (Stegh2007Bcl2L12). BCL2L12 has been shown to interact with the tumor suppressor protein p53, inhibiting its ability to bind to target gene promoters and thereby modulating p53-dependent apoptosis (Fendri2010BCL2L12). This interaction suggests a role in regulating the cellular response to DNA damage and stress.

## Clinical Significance
The BCL2L12 gene is implicated in various cancers due to its role in apoptosis regulation. In chronic lymphocytic leukemia (CLL), BCL2L12 mRNA expression is significantly elevated, correlating with advanced disease stages and reduced overall survival, suggesting its potential as a prognostic biomarker (Papageorgiou2011The). In acute myeloid leukemia (AML), high BCL2L12 expression is associated with adverse prognosis, increased likelihood of relapse, and resistance to chemotherapy, marking it as a significant prognostic marker (Thomadaki2012Overexpression).

In glioblastoma multiforme (GBM), BCL2L12 is overexpressed and contributes to tumor resistance to apoptosis by inhibiting the p53 tumor suppressor pathway, which is crucial for cell cycle regulation and apoptosis (Stegh2010Glioma). In breast cancer, BCL2L12 expression is linked to early-stage tumors and is associated with longer disease-free and overall survival, indicating a favorable prognosis (Talieri2003Expression). In colon cancer, high BCL2L12 expression correlates with less aggressive tumors and improved survival outcomes, suggesting its role as a favorable prognostic marker (Kontos2008Quantitative).

## Interactions
BCL2L12 interacts with several proteins, playing a significant role in glioblastoma multiforme (GBM) by modulating apoptosis and p53 signaling. It binds to the p53 tumor suppressor protein, forming complexes primarily in the nucleus. This interaction inhibits p53's ability to bind to the promoter elements of its target genes, such as DR5, Puma, Noxa, p21, and cyclin G1, thereby repressing p53-dependent transcriptional activity (Stegh2010Glioma). BCL2L12 also interacts with effector caspases, particularly caspase-7, inhibiting its maturation and activity, which contributes to apoptosis resistance in GBM (Stegh2007Bcl2L12).

In addition to its interactions with p53 and caspases, BCL2L12 has been shown to interact with Bcl-xL, a member of the Bcl-2 protein family, through a BH3-like domain located between residues 192-220 (YANG2015Bcl2L12). BCL2L12 also binds to GSK3β, a kinase involved in various cellular processes, with the interaction occurring through the BCL2L12 fragment spanning amino acids 153-191 (Chou2012GSK3β). These interactions highlight BCL2L12's role in modulating apoptosis and contributing to the pathogenesis of glioblastoma.


## References


[1. (Papageorgiou2011The) Sotirios G. Papageorgiou, Christos K. Kontos, Vassiliki Pappa, Hellinida Thomadaki, Frida Kontsioti, John Dervenoulas, Efstathios Papageorgiou, Theofanis Economopoulos, and Andreas Scorilas. The novel member of the bcl2 gene family, bcl2l12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker. The Oncologist, 16(9):1280–1291, July 2011. URL: http://dx.doi.org/10.1634/theoncologist.2010-0349, doi:10.1634/theoncologist.2010-0349. This article has 31 citations.](https://doi.org/10.1634/theoncologist.2010-0349)

[2. (Korbakis2012Quantitative) Dimitrios Korbakis and Andreas Scorilas. Quantitative expression analysis of the apoptosis-related genes bcl2, bax and bcl2l12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Tumor Biology, 33(3):865–875, January 2012. URL: http://dx.doi.org/10.1007/s13277-011-0313-z, doi:10.1007/s13277-011-0313-z. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s13277-011-0313-z)

[3. (Thomadaki2012Overexpression) Hellinida Thomadaki, Konstantinos V. Floros, Sonja Pavlovic, Natasa Tosic, Dimitrios Gourgiotis, Milica Colovic, and Andreas Scorilas. Overexpression of the novel member of the bcl2 gene family, bcl2l12, is associated with the disease outcome in patients with acute myeloid leukemia. Clinical Biochemistry, 45(16–17):1362–1367, November 2012. URL: http://dx.doi.org/10.1016/j.clinbiochem.2012.06.012, doi:10.1016/j.clinbiochem.2012.06.012. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.clinbiochem.2012.06.012)

[4. (Fendri2010BCL2L12) Ali Fendri, Christos K. Kontos, Abdelmajid Khabir, Raja Mokdad-Gargouri, and Andreas Scorilas. Bcl2l12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. Molecular Medicine, 17(3–4):163–171, December 2010. URL: http://dx.doi.org/10.2119/molmed.2010.00056, doi:10.2119/molmed.2010.00056. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.2119/molmed.2010.00056)

[5. (YANG2015Bcl2L12) MING-CHANG YANG, JOON-KHIM LOH, YI-YANG LI, WEN-SHENG HUANG, CHIA-HUA CHOU, JIIN-TSUEY CHENG, YENG-TSENG WANG, ANN-SHUNG LIEU, SHEN-LONG HOWNG, YI-REN HONG, and AN-KUO CHOU. Bcl2l12 with a bh3-like domain in regulating apoptosis and tmz-induced autophagy: a prospective combination of abt-737 and tmz for treating glioma. International Journal of Oncology, 46(3):1304–1316, January 2015. URL: http://dx.doi.org/10.3892/ijo.2015.2838, doi:10.3892/ijo.2015.2838. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.2015.2838)

[6. (Chou2012GSK3β) Chia-Hua Chou, An-Kuo Chou, Ching-Chih Lin, Wei-Jay Chen, Chih-Chang Wei, Ming-Chang Yang, Ching-Mei Hsu, For-Wey Lung, Joon-Khim Loh, Shen-Long Howng, and Yi-Ren Hong. Gsk3β regulates bcl2l12 and bcl2l12a anti-apoptosis signaling in glioblastoma and is inhibited by licl. Cell Cycle, 11(3):532–542, February 2012. URL: http://dx.doi.org/10.4161/cc.11.3.19051, doi:10.4161/cc.11.3.19051. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.4161/cc.11.3.19051)

[7. (Stegh2011Beyond) Alexander H. Stegh and Ronald A. DePinho. Beyond effector caspase inhibition: bcl2l12 neutralizes p53 signaling in glioblastoma. Cell Cycle, 10(1):33–38, January 2011. URL: http://dx.doi.org/10.4161/cc.10.1.14365, doi:10.4161/cc.10.1.14365. This article has 56 citations and is from a peer-reviewed journal.](https://doi.org/10.4161/cc.10.1.14365)

[8. (Talieri2003Expression) Maroulio Talieri, Eleftherios Diamandis, Nikos Katsaros, Dimitrios Gourgiotis, and Andreas Scorilas. Expression of bcl2l12, a new member of apoptosis-related genes, in breast tumors. Thrombosis and Haemostasis, 89(06):1081–1088, 2003. URL: http://dx.doi.org/10.1055/s-0037-1613411, doi:10.1055/s-0037-1613411. This article has 31 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1055/s-0037-1613411)

[9. (Stegh2007Bcl2L12) Alexander H. Stegh, Hyunggee Kim, Robert M. Bachoo, Kristin L. Forloney, Jean Zhang, Harald Schulze, Kevin Park, Gregory J. Hannon, Junying Yuan, David N. Louis, Ronald A. DePinho, and Lynda Chin. Bcl2l12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes &amp; Development, 21(1):98–111, January 2007. URL: http://dx.doi.org/10.1101/gad.1480007, doi:10.1101/gad.1480007. This article has 124 citations.](https://doi.org/10.1101/gad.1480007)

[10. (Kontos2008Quantitative) Christos K. Kontos, Iordanis N. Papadopoulos, and Andreas Scorilas. Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene bcl2l12 in colon cancer. bchm, 389(12):1467–1475, October 2008. URL: http://dx.doi.org/10.1515/BC.2008.173, doi:10.1515/bc.2008.173. This article has 51 citations.](https://doi.org/10.1515/BC.2008.173)

[11. (Stegh2010Glioma) Alexander H. Stegh, Cameron Brennan, John A. Mahoney, Kristin L. Forloney, Harry T. Jenq, Janina P. Luciano, Alexei Protopopov, Lynda Chin, and Ronald A. DePinho. Glioma oncoprotein bcl2l12 inhibits the p53 tumor suppressor. Genes &amp; Development, 24(19):2194–2204, September 2010. URL: http://dx.doi.org/10.1101/gad.1924710, doi:10.1101/gad.1924710. This article has 70 citations.](https://doi.org/10.1101/gad.1924710)

[12. (Scorilas2001Molecular) Andreas Scorilas, Lianna Kyriakopoulou, George M. Yousef, Linda K. Ashworth, Aku Kwamie, and Eleftherios P. Diamandis. Molecular cloning, physical mapping, and expression analysis of a novel gene, bcl2l12, encoding a proline-rich protein with a highly conserved bh2 domain of the bcl-2 family. Genomics, 72(2):217–221, March 2001. URL: http://dx.doi.org/10.1006/GENO.2000.6455, doi:10.1006/geno.2000.6455. This article has 115 citations and is from a peer-reviewed journal.](https://doi.org/10.1006/GENO.2000.6455)